Pfizer 2010 Annual Report Download - page 27

Download and view the complete annual report

Please find page 27 of the 2010 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 120

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120

Financial Review
Pfizer Inc. and Subsidiary Companies
Revenues—Major Biopharmaceutical Products
Revenue information for several of our major Biopharmaceutical products follows:
(MILLIONS OF DOLLARS) YEAR ENDED DECEMBER 31, % CHANGE
PRODUCT PRIMARY INDICATIONS 2010 2009 2008 10/09 09/08
Lipitor Reduction of LDL cholesterol $10,733 $11,434 $12,401 (6) (8)
Enbrel(a), (b) Rheumatoid, juvenile rheumatoid and
psoriatic arthritis, plaque psoriasis and
ankylosing spondylitis
3,274 378 — **
Lyrica Epilepsy, post-herpetic neuralgia and
diabetic peripheral neuropathy,
fibromyalgia
3,063 2,840 2,573 810
Prevnar/Prevenar 13(a) Vaccine for prevention of invasive
pneumococcal disease
2,416 ——**
Celebrex Arthritis pain and inflammation, acute pain 2,374 2,383 2,489 —(4)
Viagra Erectile dysfunction 1,928 1,892 1,934 2(2)
Xalatan/Xalacom Glaucoma and ocular hypertension 1,749 1,737 1,745 1—
Effexor(a) Depression and certain anxiety disorders 1,718 520 — **
Norvasc Hypertension 1,506 1,973 2,244 (24) (12)
Prevnar/Prevenar(7-valent)(a) Vaccine for prevention of invasive
pneumococcal disease
1,253 287 — **
Zyvox Bacterial infections 1,176 1,141 1,115 32
Sutent Advanced and/or metastatic renal cell
carcinoma (mRCC) and refractory
gastrointestinal stromal tumors (GIST)
1,066 964 847 11 14
Premarin family(a) Menopause 1,040 213 — **
Geodon/Zeldox Schizophrenia; acute manic or mixed
episodes associated with bipolar
disorder; maintenance treatment of
bipolar mania
1,027 1,002 1,007 2(1)
Detrol/Detrol LA Overactive bladder 1,013 1,154 1,214 (12) (5)
Zosyn/Tazocin(a) Antibiotic 952 184 — **
Genotropin Replacement of human growth hormone 885 887 898 —(1)
Vfend Fungal infections 825 798 743 37
Chantix/Champix An aid to smoking cessation 755 700 846 8(17)
Protonix(a) Gastroesophageal reflux disease 690 68 — **
BeneFIX(a) Hemophilia 643 98 — **
Zoloft Depression and certain anxiety disorders 532 516 539 3(4)
Caduet Reduction of LDL cholesterol and
hypertension
527 548 589 (4) (7)
Aromasin Breast cancer 483 483 465 —4
Revatio Pulmonary arterial hypertension (PAH) 481 450 336 734
Pristiq(a) Depression 466 82 — **
Medrol Inflammation 455 457 459 ——
Aricept(c) Alzheimer’s disease 417 432 482 (3) (10)
Zithromax/Zmax Bacterial infections 415 430 429 (3) —
Cardura Hypertension/Benign prostatic
hyperplasia
413 457 499 (10) (8)
ReFacto AF/Xyntha(a) Hemophilia 404 47 — **
BMP2(a) Development of bone and cartilage 400 81 — **
Rapamune(a) Immunosuppressant 388 57 — **
Fragmin Anticoagulant 341 359 316 (5) 14
Tygacil(a) Antibiotic 324 54 — **
Alliance revenues(d) Various 4,084 2,925 2,251 40 30
All other(e) Various 8,307 7,417 7,753 12 (4)
(a) Legacy Wyeth products. Legacy Wyeth operations are included for a full year in 2010. In accordance with Pfizer’s domestic and international year-
ends, 2009 includes approximately two-and-a-half months of Wyeth’s U.S. operations and approximately one-and-a-half months of Wyeth’s
international operations.
(b) Outside the U.S. and Canada.
(c) Represents direct sales under license agreement with Eisai Co., Ltd.
(d) Enbrel (in the U.S. and Canada)(a) , Aricept, Exforge, Rebif and Spiriva.
(e) Includes legacy Pfizer products in 2010, 2009 and 2008. Also includes legacy Wyeth products in 2010 and, as described in note (a) above, during a
portion of 2009.
* Calculation not meaningful.
Certain amounts and percentages may reflect rounding adjustments.
2010 Financial Report 25